




Hikal Limited

FY19: Net Profit Crosses Rs. 100 Crore

- ✓ Sales of Rs. 1,590 Crore; Growth of 22%
- ✓ EBITDA of Rs. 298 Crore; Growth of 23%
- ✓ PAT of Rs. 103 Crore; Growth of 34%
- ✓ Total Dividend for the year 60% (incl. interim dividend of 30%)

Mumbai, 9th May, 2019: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its financial results for the quarter and full year ended 31st March, 2019.

Highlights for 12 months ended 31st March, 2019



Performance highlights for the 12 months ended 31st March, 2019

- Sales up 22% to Rs. 1,590 crore as compared to Rs. 1,300 crore in the corresponding period of the previous year
- EBITDA up 23% to Rs. 298 crore as compared to Rs. 242 crore in the corresponding period of the previous year
- PAT up 34% to Rs. 103 crore as compared to Rs. 77 crore in the corresponding period of the previous year


Segmental Performance for the 12 months ended 31st March, 2019

- Crop Protection sales up 19% to Rs. 651 crore as compared to Rs. 547 crore in the corresponding period of the previous year
- Pharmaceutical sales up 25% to Rs. 939 crore as compared to Rs. 753 crore in the corresponding period of the previous year





Highlights for quarter ended 31st March, 2019



Performance highlights for the quarter ended 31st March, 2019

- Sales up 17% to Rs. 458 crore as compared to Rs. 390 crore in the corresponding period of the previous year
- EBITDA up 18% to Rs. 84 crore as compared to Rs. 71 crore in the corresponding period of the previous year
- PAT up 32% to Rs. 33 crore as compared to Rs. 25 crore in the corresponding period of the previous year

Segmental Performance for the quarter ended 31st March, 2019

- Crop Protection sales up 13% to Rs. 198 crore as compared to Rs. 176 crore in the corresponding period of the previous year
- Pharmaceutical sales up 21% to Rs. 259 crore as compared to Rs. 215 crore in the corresponding period of the previous year

Awards and Accolades

- > Certified as a 'Great Place to Work' by the Great Place to Work[®] Institute
- Conferred with the 'ET NOW CSR Leadership Award' for Best Corporate Social Responsibility Practices by the World CSR Congress
- Recognized as the 'National Best Employer Brands 2018' by the Global Employer Branding Institute and World HRD Congress
- Won the coveted Confederation of Indian Industry (CII)'s 'Significant Achievement in HR Excellence' award at the CII National HR Excellence Award Confluence





Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,

"We have achieved a significant milestone in our company by crossing Rs. 100 Crores in net profit for FY19 representing a substantial growth of 34%, with a revenue of 1,590 Crores, representing a healthy growth of 22%. Our Crop Protection Division has clocked a revenue growth of 19% and the Pharmaceutical Division has grown by 25%. Our EBITDA has grown by 23% and we expect further improvement next financial year.

Based on our performance, the Board of Directors had declared 30% as an Interim Dividend and recommended a Final Dividend of 30% on equity shares for the year ended March 2019, subject to shareholder's approval, which would make the total dividend for the year, 60%.

Both the businesses showed growth from existing and new products. We are implementing significant capital investment in both our divisions for new capacity which will come on stream by next financial year. Our Balance Sheet continues to remain strong with Net Debt to Equity of 0.79 as on March 2019. We are positive on the future outlook of our business.

The recent awards won by the Company is testimony to the concerted efforts put in by all Hikalites reinforcing our commitment to excellence."





About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care[®] certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact	
Company :	Investor Relations Advisors :
Hikal Limited CIN: L24200MH1988PTC048028	Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285
Mr. Anish Swadi anish_swadi@hikal.com	Ms. Payal Dave / Mr. Jigar Kavaiya payal.dave@sgapl.net / jigar.kavaiya@sgapl.net +91 9819916314 / +91 9920602034
www.hikal.com	www.sgapl.net